AstraZeneca Phase 3 Lung Cancer Failure

AstraZeneca has terminated a Phase 3 lung cancer trial after a bispecific antibody failed to demonstrate superiority over Keytruda (pembrolizumab), MSD's dominant checkpoint inhibitor. This represents a direct validation of Keytruda's entrenched position as the standard-of-care in non-small cell lung cancer and removes a competitive threat for Merck near-term. AstraZeneca's pipeline setback is material given that oncology, and specifically lung cancer, accounts for a significant portion of its growth narrative—the failure raises questions about valuation support from the oncology segment. The positioning implication is long MRK (Keytruda reinforced) and cautious on AZN.